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Abstract 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic 
neurons in the nigrostriatal pathway. The etiology of PD remains unclear and most cases are 
sporadic, however genetic mutations in more than 20 proteins have been shown to cause inherited 
forms of PD. Many of these proteins are linked to mitochondrial function, defects in which are a 
central characteristic of PD. Post-translational modifications (PTMs) allow rapid and reversible control 
over protein function. Largely focussing on mitochondrial dysfunction in PD, here we review findings 
on the PTMs phosphorylation, SUMOylation and ubiquitination that have been shown to affect PD-
related proteins.    
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1. Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder affecting around 1-
3% of the elderly population over 65 years. The loss of dopaminergic neurons in the susbstantia nigra 
(SN) pars compacta and Lewy body (LB) inclusions are the main pathological hallmarks of PD. 
Currently, it is known that PD patients can present non-motor symptoms (olfactory dysfunction, 
dementia, cognitive decline) prior to developing the characteristic motor symptoms, rigidity, resting 
tremor and bradykinesia1. Most PD cases are sporadic but a number of genetic and environmental 
risk factors have been identified. Furthermore, mutations in more than 20 genes have been shown to 
cause autosomal dominant or recessive forms of PD2. Amongst these, autosomal dominant mutations 
in alpha-synuclein (α-syn), leucine-rich repeat kinase 2 (LRRK2), and recessive mutations in the 
mitochondria-associated proteins PTEN-induced putative kinase 1 (PINK1), Parkin and DJ-1 are 
amongst the most common (Figure 1). Here, we briefly review how these proteins control neuronal 
and mitochondrial function, and discuss how PTMs of these proteins control their behavior, focusing 
on phosphorylation, SUMOylation and ubiquitination.   
2. The PD-associated proteins, alpha-synuclein, PINK1, Parkin and DJ-1: 
α-Syn is a soluble protein highly expressed presynaptically in neurons and can be found as an α-
helical structure associated with phospholipids or in an unfolded conformation in the cytosol3,4 
Misfolded α-Syn forms oligomers and fibrils that are highly toxic to cells, and is the main component of 
Lewy Bodies, intracellular inclusions characteristic of PD which may promote neuroprotection through 
sequestration of toxic α-Syn fibrils, or directly contribute to neurotoxicity4. Although its physiological 
function remains not well understood, α-syn has been strongly implicated in synaptic plasticity and 
neurotransmitter release5. Mutations in alpha-synuclein were the first identified genetic cause of PD 
and subsequently a number of missense mutations, as well as gene duplications, have been 
observed in PD patients2  
Mitochondria undergo constant rounds of fission (mitochondrial division), or fusion. These processes, 
termed mitochondrial dynamics, allow the cell to adapt to fluctuating energy demands, as well as 
maintaining mitochondrial quality through partitioning damaged mitochondria for subsequent 
degradation by mitophagy6. A large body of evidence implicates mitochondrial dysfunction in PD, and 
alterations in the balance between mitochondrial fusion and fission, and defects in mitochondrial 
quality control, are observed in both human patients and animal and cell culture models6,7. At the 
molecular level, mitochondrial fusion and fission are controlled by distinct GTPases – Mfn1 and 2 and 
OPA1 for fusion, and Drp1 for fission8. The balance of activity of these GTPases ultimately 
determines the balance between fission and fusion, and the morphology of the mitochondrial network. 
For example, under stress conditions, an imbalance in mitochondrial Drp1 leads to apoptosis9, and in 
sporadic PD, aberrant mitochondrial dynamics and the consequent cellular dysfunction have been 
attributed to Drp1-dependent mitochondrial fragmentation10,11. Thus, factors that control the 
localization and activity of Drp-1 are highly relevant to the pathology of PD. 
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Both PINK1 and Parkin are required in order to maintain mitochondrial quality control. PINK1 is a Ser-
Thr kinase with a mitochondrial targeting sequence. In healthy conditions, PINK1 is imported to 
mitochondria, cleaved and degraded. When there is mitochondrial damage, it accumulates on the 
cytosolic face of the outer membrane and initiates a quality control pathway involving Parkin6. Parkin 
is a cytosolic E3 ubiquitin ligase recruited to damaged mitochondria by PINK1. PINK1 activates Parkin 
directly via phosphorylation and indirectly through phosphorylation of ubiquitin, leading to maximal 
Parkin E3 ligase activity12. Parkin can also be found in synaptic vesicles and LB inclusions10,13, 
facilitating autophagic degradation of intracellular protein aggregates (aggrephagy)14. Nonetheless, it 
is most well characterized for its role in ubiquitinating mitochondrial target proteins, either to restore 
mitochondrial proteostasis by targeting misfolded proteins for degradation, or to target the whole 
organelle for removal by mitophagy. Importantly, amongst the identified targets for Parkin-mediated 
ubiquitination, are the fusion GTPases Mfn1 and 215 and the fission GTPase Drp18 highlighting Parkin 
as a central determinant of mitochondrial morphology and quality control.  
The small protein deglycase DJ-1, ubiquitously expressed in almost all cells and tissues, is present in 
the brain in the cytoplasm, nucleus and to a lesser extension at mitochondria. DJ-1, among other 
things, is implicated in cellular redox homeostasis, mitochondrial protection, inhibition of α-syn 
aggregation, neuroprotection from dopamine toxicity and transcription of tyrosine hydroxylase (TH)16, 
however its specific role in PD still remains unclear.  
The kinase LRRK2 is expressed throughout the brain, in some peripheral organs and immune cells. It 
is involved in pathways including regulation of protein synthesis, neural cell morphology and 
mitochondrial function. Moreover, inclusion body formation and nigrostriatal dopaminergic 
neurodegeneration have been attributed to site-specific LRRK2-kinase activity17,18. Interestingly, 
similar to PINK1/Parkin, LRRK2 has been linked to mitochondrial quality control, and has been shown 
to interact with Drp118. Moreover, expression of pathogenic LRRK2 mutants in neurons induces 
mitochondrial fragmentation through Drp119, further highlighting the balance of mitochondrial fusion 
and fission as a central factor in PD pathogenesis. Nonetheless, although the exact function and 
targets of LRRK2 kinase activity are still unclear, mutations in LRRK2 represent the most common in 
PD20, the most frequent of which is a point mutation, G2019S2  
3. Phosphorylation, ubiquitination and SUMOylation 
PTMs play crucial roles in almost every biological process. They consist of alterations that occur on a 
protein after it is translated by the ribosome, affecting its function, stability, localization, interaction 
with other proteins and degradation10,21-24. The ability to modify existing proteins allows the cell to 
respond rapidly to stimuli, and this is particularly important in neurons, where neurotransmission 
typically occurs on the millisecond timescale.  
Phosphorylation is the addition of a phosphate group on Ser (86.4% of cases), Thr (11.8% of cases) 
or Tyr (1.8% of cases) residues of substrate proteins by a protein kinase, while dephosphorylation is 
performed by a protein phosphatase25. This process of phosphorylation and dephosphorylation 
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orchestrates a vast array of cellular processes, regulating protein functions in response to external 
stimuli and allowing cells to sense and actively respond to changes in their environment24-27.  
SUMOylation consists of the conjugation of different isoforms of the small ubiquitin like modifier 
protein (SUMO) to target proteins. SUMO is a ~11 kDa protein that is covalently conjugated to Lys 
residues in target proteins, usually within a consensus motif, altering their function, stability, or 
subcellular localization. So far, three validated SUMO isoforms (SUMO1-3) have been identified in 
vertebrates, but since SUMO2 and 3 differ by only four amino acids, they are usually collectively 
referred to as SUMO2/3. SUMOylation occurs via the action of a 3-step enzymatic cascade involving 
an E1 enzyme, a sole E2 conjugating enzyme, Ubc9, and a number of E3 ligase enzymes 
Furthermore, SUMOylation can be reversed via the action of SUMO-specific proteases, the most well 
characterized of which are the sentrin-specifc proteases (SENPs)28 .  
Ubiquitination is also a key process for cell survival and maintenance. The protein ubiquitin (Ub) is 
responsible for marking proteins for degradation by being covalently conjugated to Lys residues, 
either as a monomer, or as an array of complex ubiquitin chains resulting from the conjugation of 
ubiquitin molecules to one another, via several internal lysine residues29. It is known that the 
deregulation of ubiquitination can lead to cellular pathology, including the accumulation of misfolded 
proteins during neurodegenerative diseases30. In addition to this function, ubiquitin can be attached to 
proteins to control their protein-protein interactions, protein subcellular localization and protein activity, 
depending on the type of ubiquitin chain attached to the target24.  
It is becoming increasingly apparent that PTMs are involved in diverse cellular processes by acting 
directly on a target protein or by complex cross-regulation between modifications, and alterations in 
phosphorylation, SUMOylation and ubiquitination have been observed in a number of disease states31 
, suggesting that perturbations in these pathways may influence disease progression and pathology. 
In PD it has been shown that all three PTMs play a role in protein aggregation, exocytosis, and 
degradation5,21-23,27,32-34. Therefore, comprehending how these modifications control the function of 
PD-related proteins, and how these PTMs are altered in disease, could bring new insights into the 
etiology of the disease, as well as identify potential targets for therapeutic intervention. Thus, our aim 
in this mini-review is to summarize what we know so far about how these three PTMs can affect the 
PD-related proteins α-syn, Parkin, PINK1, DJ-1, LRRK2 and Drp1 (Figure 2). 
3.1  PTMs of α-syn 
α-Syn is considered to be a key protein in PD pathogenesis in both familial and sporadic forms. In 
humans, it is encoded by the SCNA gene, and mutations in this gene were the first genetic alterations 
to be associated with the etiology of PD35. To date a total of six PD-related point mutations (A53T, 
A30P, E64K, H50Q, G51D, and A53E) have been identified35. Recent insights have shown that this 
protein may also act like a prion, propagating from one neuron to another, therefore enhancing brain 
degeneration33,35,36. Phosphorylation of α-syn at Ser-129 exacerbates the formation of α-syn 
inclusions, with over 90% of α-syn in LBs being phosphorylated at this residue, resulting in increased 
toxicity and neuronal death5,23,27,34. In a study by Karampetsou and colleagues (2017), α-syn was 
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injected into mouse striatum in its wild type form versus its phosphorylated form, and they observed 
that phosphorylated α-syn demonstrated enhanced pathology in the SN compared to WT α-syn, 
increasing dopaminergic neuronal loss27. It is known that various kinases can contribute to this over-
phosphorylation at Ser-129, and one example is the inflammation kinase PKR, highlighting how 
neuroinflammation can play a role in PD progression through α-syn dysfunction5,23. 
SUMOylation also plays a role in α-syn fate, influencing its aggregation, exocytosis and 
degradation21,22,32,33. Potentially supporting the idea that α-syn may act as a prion, spreading 
degeneration, Kunadt and colleagues (2015) have shown that α-syn is present in extracellular 
vesicles from human cerebrospinal fluid and that sorting of α-syn in extracellular vesicles is mediated 
by SUMOylation33. Furthermore, Abeywardana and colleagues (2015) have shown that SUMOylation 
can inhibit α-syn aggregation in a site and isoform-specific manner. Their results showed that SUMO1 
is a more potent blocker of aggregation than SUMO3 and that SUMOylation at the acceptor site Lys-
102 of α-syn leads to a more pronounced inhibition of aggregation than the corresponding 
modification at Lys-9632. However, the exact role of SUMOylation in α-syn aggregation is still unclear. 
It is possible that this divergence occurs due to different outcomes for each specific site that can be 
affected, as well as because of the specific actions of each isoform.  
Ubiquitination is also a key process in cell survival, and Rott and colleagues (2017) have shown that 
there may be a cross-regulation between this modification and SUMOylation, in which the conjugation 
of SUMO proteins to α-syn decreases its ubiquitination, causing its accumulation and aggregation into 
inclusions22. 
These interactions between PTMs in regulating α-syn accumulation create a very complex panel to be 
clarified. Currently, the exact function of α-syn is still poorly understood, which makes this 
investigation even more challenging. Nonetheless, understanding the influence of PTMs on this 
protein will provide important insights into both its normal and pathological roles, potentially opening 
new avenues for the design of therapeutic interventions aimed at targeting PTMs of α-syn. 
3.2  PTMs of PINK, Parkin, DJ-1 and Drp1 
The mitochondrial Ser/Thr kinase PINK1, the cytosolic E3-ubiquitin ligase Parkin, the protein DJ-1 
and the GTPase Drp1 share overlapping roles in determining mitochondrial dynamics and quality 
control through regulation of mitophagy, fusion and fission, and oxidative stress responses10,16. 
Cellular control over the activity of these proteins is thus tightly regulated, and each of them has been 
reported to be targeted by several PTMs.  
When mitochondria undergo damage, PINK1 stabilizes at the mitochondrial outer membrane (MOM) 
and phosphorylates Ub and Parkin, both at Ser-65. Phosphorylated Ub (p-Ub) then binds and 
activates Parkin which, in turn, then ubiquitinates other MOM proteins37. Interestingly, studies have 
suggested that p-Ub at Ser-65 could be a biomarker for PD diagnosis since it is found in cytoplasmic 
granules near LBs and it appears to increase with aging and in sporadic PD38. Several PD-linked 
mutations occur at kinase domain of PINK1, abolishing its catalytic activity and the consequent 
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recruitment of Parkin6 Furthermore, mutations in Parkin represent the most common autosomal 
recessive causes of PD2 highlighting dysfunction in the PINK1-Parkin pathway as a recurring feature 
of PD pathology.  
It has been shown that PINK1 autophosphorylation on Ser-228, Ser-402 and Ser-465 increase its 
ability to phosphorylate and recruit Parkin, induce mitophagy and initiate substrate clearance39-41. In 
particular, phosphorylation on Ser-465 has been linked to PINK1 degradation, being important to 
maintain cellular levels of PINK1 and mediate Parkin translocation40, but phosphorylation of Thr-175 
and Thr-217 in PINK1 have been reported to be crucial for Parkin translocation24. Ubiquitination has 
also been shown to have an important role in regulating PINK1 levels inside the cell, maintaining it at 
low levels under basal conditions as a result of poly-ubquitination, which has been reported to occur 
primarily at Lys-13713. 
Parkin functions as an E3-Ub ligase, ubiquitinating a wide variety of substrates via Ub chain formation 
at Lys-48 leading to proteasomal degradation and at Lys-63 to recruit autophagy adaptors, although 
this latter role remains controversial24,42. It has been suggested that Ub-Parkin is its inactive form, 
since Ub-Parkin was found in LBs in PD patient brains24. However, mono-ubiquitination at different 
sites is thought to activate Parkin, and to be involved in the regulation of its subcellular localization24. 
Furthermore Parkin ubiquitination at Lys-27, Lys-48, and Lys-76 in its N-terminal Ubl domain can 
regulate Parkin interaction with its targets42 and the inhibition of deubiquitinating enzymes that act on 
Parkin have been shown to improve motor behavior and mediate neuroprotection in in vivo PD 
models38. Parkin E3-Ub activity can be lost when phosphorylated at Tyr-143 by c-Abl in an in vivo PD 
model, which is consistent with increased levels of c-Abl and p-Tyr-143 Parkin observed in post 
mortem brains from PD patients24. In addition, phosphorylation of Parkin at Ser-94 is involved in 
regulation of spontaneous dopamine release from neuron terminals and survival rates24.  
Another PTM that seems to play a role on in the PINK1/Parkin pathway is SUMOylation. While not 
reported to be directly covalently modified by SUMO, Parkin has been shown to bind SUMO non-
covalently, increasing its self-ubiquitination, and altering Parkin cellular localization by translocating it 
into the nucleus, which decreases the amount of Parkin available for mitochondrial recruitment by 
PINK110.  
It has been reported that, under oxidative stress conditions, Parkin interacts with DJ-1 without 
promoting its ubiquitination16. In contrast, the PD-linked DJ-1 mutant, L166P, can be ubiquitinated by 
Parkin but, somewhat counter-intuitively, this does not lead to its degradation, but instead promotes 
its cellular stability16. DJ-1 has also been reported to be SUMOylated, with this modification appearing 
essential for its full activity and reducing its degradation. In addition, the SUMOylated form of DJ-1 
also seems to support the elimination of reactive oxidative species during oxidative stress10.  
The GTPase Drp1 is a central determinant of mitochondrial function and dynamics through mediating 
fission. Drp1 function is very tightly regulated by multiple PTMs, including phosphorylation, 
ubiquitination and SUMOylation10. Drp1 can be phosphorylated at different Ser residues and its 
mitochondrial recruitment is phosphorylation site-dependent to either enhance or reduce 
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mitochondrial fission9. Previous studies have reported that PD toxin-based cell models increase Drp1 
phosphorylation at Ser-616 and enhance Drp1 mitochondrial recruitment and consequent 
mitochondrial fission8,11. Furthermore, Drp1 can be ubiquitinated by Parkin, promoting its degradation 
and counteracting mitochondrial fission. However, Zang and colleagues (2016) have shown that 
Parkin binding to Drp1 is decreased in a 1-methyl-4-phenylpyridinium (MPP+) PD cell model, leading 
to an increase in Drp1 levels. Furthermore, in the same study it was shown that Parkin attenuates the 
toxicity of excessive Drp1 activity in MPP+-treated cells8. Drp1 is a direct target of both SUMO1 and 
SUMO2/3 and can be SUMOylated at one or more Lys residues. Whereas SUMOylation of Drp1 by 
SUMO1 enhances its mitochondrial recruitment and promotes fragmentation and apoptosis, 
SUMOylation by SUMO2/3 decreases mitochondrial localization and prevents cell death9,10. Although 
it is well established that disruption of mitochondrial dynamics is a central feature of PD pathogenesis, 
the roles of Drp1 SUMOylation in PD remain to be defined. 
3.4  PTMs of LRRK2 
LRRK2 is a large protein kinase characterized by several domains, including various protein-protein 
interaction regions, a GTPase domain and a kinase domain. This protein localizes to the cytosol in a 
monomeric and inactive form and in the membrane predominantly as active dimers. LRRK2 exhibits 
both kinase and GTPase activity, and there is evidence to suggest that both of these activities 
contribute to the pathogenicity of LRRK2 mutants in PD. LRRK2 exhibits autophosphorylation activity 
on Ser-910, Ser-935 and Ser-1292 linked to regulation of its kinase activity while phosphorylation of 
LRRK2 GTPase domain can stimulate GTP hydrolysis17. Among the seven pathogenic mutations 
reported in LRRK2, the most common, G2019S (substitution of Gly 2019 with a Ser), occurs in the 
kinase domain and increases its phosphorylation activity18. Interestingly, increased levels of 
phosphorylated Ser-1292 were found in the urine of idiopathic PD patients with the LRRK2 G2019S 
mutation and this also correlated with the severity of cognitive impairment and difficulty in performing 
daily activities, suggesting it may be a useful early detection marker17. Some evidence points to an 
indirect involvement of phosphorylation on Ser-910 and Ser-935 in the reduction in neurite length 
observed in G2019S neuronal cultures26. Ser-935 phosphorylation precedes LRRK2 translocation 
from the cytosol to cellular membrane43. On the other hand, wild type LRRK2 and some PD-related 
LRRK2 mutants accumulate in cytosolic inclusions when Ser-910 and Ser-935 phosphorylation are 
inhibited17,18. Interestingly, a 36% reduction in LRRK2 phosphorylation, particularly at Ser-935, has 
been observed in SN of clinical PD patients43. The potential relevance of this site to PD pathogenesis 
has been demonstrated by examining the E193K LRRK2 mutant, a recent variant identified in an 
Italian family that influences LRRK2 biochemical properties. Fibroblast cells carring this variant exhibit 
impaired p-Ser-935 levels and upon MPP+ treatment they demonstrated increased cellular toxicity and 
abnormal mitochondrial fission19. Furthermore, Stanic and colleagues (2016) proposed that LRRK2 
phosphorylation at Ser-935 is involved in L-DOPA-induced dyskinesias (LIDs), the major side effect in 
PD therapy. Data obtained from an in vivo PD model showed a significant p-Ser-935 decrease in 
dyskinetic rats compared to non-dyskinetic rats, making this site-specific LRRK2 phosphorylation a 
potential therapeutic target for LIDs prevention44. Phosphorylation of another LRRK2 site, Ser-1627, is 
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increased in the PD LRRK2 mutation R1628P in a indirect way that upregulates the kinase activity of 
LRRK2. In the MPP+ in vitro PD model, this increased  p-Ser-1627 LRRK2 leads to a higher toxicity 
and consequently neuronal death45.  
A previous study has shown a link between increased LRRK2 ubiquitination and the inhibition of its 
kinase activity46. After dephosphorylation of Ser-935 as a result of inhibition of the kinase domain, a 
considerable amount of LRRK2 is ubiquitinated, mainly through Lys-48 and Lys-63 ubiquitin chains, 
and then degraded46. Nucifora and colleagues (2016) have shown in in vivo and in vitro models with 
G2019S LRRK2 that the E3 ligase WD repeat and SOCS box-containing protein 1 (WSB1) 
ubiquitinates LRRK2 through Lys-27 and Lys-29 linkage chains, leading to LRRK2 aggregation and 
neuronal protection, while knocking down endogenous WSB1 exacerbates neuronal toxicity30. 
Curiously, WSB1 was found in LBs of human PD post mortem tissue suggesting LRRK2 ubiquitination 
may be a signal for aggregation and neuronal protection in PD30. There is also evidence to suggest 
that the G2385R LRRK2 variant exhibits higher levels of proteasomal degradation, leading to lower 
steady state intracellular protein levels compared to wild type LRRK2, suggesting G2385R may be a  
risk  factor instead of a variant for inherited  PD47. 
Perspectives 
Understanding the function and regulation of proteins known to be central to PD pathogenesis is a 
key research question. The investment of research to discover the specific sites of PTMs of PD-
related proteins and their physiological consequences will undoubtedly contribute to our 
understanding of how these proteins work, and how this complex array of modifications control their 
function. Furthermore, determining how these modifications are perturbed in PD will highlight how 
targeting these pathways may be of therapeutic benefit.  
While a great deal of progress has been made in identifying sites of modification of PD-related 
proteins, many outstanding questions remain. Indeed, reports of the functional consequences of many 
of these modifications have been contradictory, possibly in part due to the different experimental 
models used (Table 1). Moreover, we are only just beginning to understand how crosstalk between 
multiple modifications can orchestrate target protein function. Nonetheless, targeting these pathways 
is likely to ultimately be of therapeutic benefit, and some compounds, like rifampicin and metformin, 
which are already on the market to treat other diseases, have, for example, been shown to affect α-
syn SUMOylation and phosphorylation, respectively, promoting cellular survival48,49. Another study 
focusing on mitochondrial quality control has reported a compound that enhanced PINK1 activity and, 
consequently, Parkin recruitment, promoting cellular survival38. These findings encourage new 
research into the PTMs of PD-related proteins since these modifications can potentially be targeted 
for disease-modifying strategies which aim to prevent or slow the progression of PD and, potentially, 
other neurodegenerative diseases characterized by mitochondrial dysfunction and neuronal cell 
death. In addition, through identification of specific protein PTMs that are altered in PD, it may be 
possible to use these modifications as a peripheral biomarker to allow early diagnosis50, to facilitate 
interventions aimed at slowing or reversing the symptoms of PD.   
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 Figure 1: Dopaminergic signaling and Parkinson’s disease (PD)-associated proteins. The synthesis 
pathway of dopamine can be found on the left hand side of the synaptic terminal.  Genetic and risk factors, 
like neurotoxins and environmental toxins, can alter proteins associated with PD pathogenesis and also 
induce stress conditions inside the cell stimulating the formation of Lewy bodies inclusions and ultimately 
cell death. 
 
 
 
 
 
Figure 2: Summary of the effects of Phosphorylation, SUMOylation and Ubiquitination on PD-
associated proteins. Stimulation (       ), inhibition (        ) and unknown or not investigated (       ) are 
depicted by arrows. 
Protein PTM Site Main findings Study 
α-Syn 
 
Phosphorylation Ser-129 Exacerbates the formation of α-syn inclusions, increasing toxicity and neuronal death 
5,23,27,
34 
SUMOylation Lys-102 Pronounced inhibition of aggregation 32 
SUMOylation Not specified Sorting of α-syn into extracellular vesicles 33 
SUMOylation Not specified Decreases its ubiquitination, causing its accumulation and aggregation 22 
PINK1 
 
Phosphorylation Ser-228, Ser-402 and Ser-465 
Increases its ability to phosphorylate and recruit 
Parkin 39-41 
Phosphorylation Ser-465 PINK1 degradation 30 
Phosphorylation Thr-175 and Thr-217 Parkin translocation 24 
Ubiquitination Lys-137 Decreases PINK1 levels inside the cell 13 
Parkin 
 
Phosphorylation Tyr-143 Reduces E3-ligase activity 24 
Non-covalent 
binding to 
SUMO 
Not specified Increases Parkin self-ubiquitination, changing its cellular localization by translocating it into the nucleus 10 
Ubiquitination Lys-48 Self-degradation 24,42 
Ubiquitination Lys-27, Lys-48, and Lys-76 Regulates interaction with target proteins 42 
 
 
DJ-1 
 
 
SUMOylation Not specified 
Required for full activity potential, reduces its 
degradation, contributes to elimination of reactive 
oxidative species 
10 
Drp1 
 
Phosphorylation Ser-616 Promotes mitochondrial recruitment 8,11 
Ubiquitination Not specified Promotes its degradation and counteracts mitochondrial fission 8 
SUMOylation Not specified 
SUMO1 enhances its mitochondrial recruitment and 
promotes fragmentation and apoptosis while                      
SUMO2/3 decreases mitochondrial localization and 
prevents cell death 
9,10 
LRRK2 
Phosphorylation Ser-910, Ser-935 and Ser-1292 
Linked to its kinase activity; LRRK2 translocation from 
cytosol to cellular membrane 17,5 
Ubiquitination Not specified Inhibition of its kinase activity 17 
 
Table 1. Summary of site-specific modifications.Abbreviations: α-Syn - alpha-synuclein; Drp1  - 
dynamin related protein-1;  Lys - lysine; LRRK2 - leucine-rich repeat kinase 2;  PINK1 - PTEN-induced 
putative kinase 1; Ser - serine; Thr - threonine	
	
